Agios Pharmaceuticals, Inc. SEC filings AGIO
Agios Pharmaceuticals, Inc. has 1,004 filings in SEC EDGAR's recent list, going back to Dec 7, 2015. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 24, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Jun 18, 2026 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 18, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 20, 2024 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 21, 2022 |
| DEFA14A | Additional proxy material | May 10, 2021 | — |
| DEFA14A | Additional proxy material | Apr 8, 2021 | — |
| DEF 14A | Proxy statement | Apr 8, 2021 | May 20, 2021 |
| DEFA14A | Additional proxy material | Mar 15, 2021 | — |
| DEFM14A | Filing | Feb 11, 2021 | — |
| PREM14A | Filing | Jan 29, 2021 | Jan 29, 2021 |
| DEFA14A | Additional proxy material | Jan 12, 2021 | — |
| DEFA14A | Additional proxy material | Jan 11, 2021 | — |
| DEFA14A | Additional proxy material | Dec 23, 2020 | — |
| DEFA14A | Additional proxy material | Dec 22, 2020 | — |
| DEFA14A | Additional proxy material | Dec 21, 2020 | — |
| DEFA14A | Additional proxy material | Dec 21, 2020 | — |
| DEFA14A | Additional proxy material | Dec 21, 2020 | — |
| DEFA14A | Additional proxy material | Apr 16, 2020 | — |
| DEF 14A | Proxy statement | Apr 16, 2020 | May 28, 2020 |
| DEFA14A | Additional proxy material | Apr 18, 2019 | — |
| DEF 14A | Proxy statement | Apr 18, 2019 | May 29, 2019 |
| DEFA14A | Additional proxy material | Apr 18, 2018 | — |
| DEF 14A | Proxy statement | Apr 18, 2018 | May 31, 2018 |
| DEFA14A | Additional proxy material | Apr 24, 2017 | — |
| DEF 14A | Proxy statement | Apr 24, 2017 | Jun 13, 2017 |
| DEFA14A | Additional proxy material | Jun 16, 2016 | — |
| DEFA14A | Additional proxy material | Apr 27, 2016 | — |
| DEF 14A | Proxy statement | Apr 27, 2016 | Jun 21, 2016 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AGIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1439222
- Former names
- AGIOS PHARMACEUTICALS INC (until Jul 16, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.